1-2 of 2
Ziyan Guo
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Trial in progress: A phase 1 study to evaluate the safety and preliminary efficacy of arlocabtagene autoleucel (arlo-cel), a GPRC5D-targeted chimeric antigen receptor (CAR) T cell therapy, in combination with mezigdomide (MEZI) in patients (pts) with relapsed/refractory multiple myeloma (RRMM)

Free
Susan Bal, Luciano Costa, Nizar Bahlis, Myo Htut, Omar Nadeem, Krina Patel, Scott Solomon, Jaclyn Davis, Ziyan Guo, Kevin Hsu, Hongxiang Hu, Krishna R. Juluri, Jessica Katz, Timothy Pulham, Safiyyah Ziyad, Sham Mailankody
Journal: Blood
Blood (2025) 146 (Supplement 1): 5807.
https://doi.org/10.1182/blood-2025-5807
Published: 2025
Journal Articles

Assessment of pharmacodynamic efficacy biomarkers from A phase 1, first-in-human study of arlocabtagene autoleucel (arlo-cel) in relapsed and refractory multiple myeloma (RRMM)

Free
Safiyyah Ziyad, Kristina Jordahl, Hongxiang Hu, Ethan Thompson, Susan Bal, Myo Htut, Larry Anderson, Tara Gregory, Luciano Costa, Omar Nadeem, Naomey Sarkis, Ziyan Guo, Wei-Ming Kao, Allison Kaeding, Shari Kaiser, Michael Burgess, Jesús Berdeja
Journal: Blood
Blood (2025) 146 (Supplement 1): 2223.
https://doi.org/10.1182/blood-2025-2223
Published: 2025